Search
ATMPs and CAR-T: the uptake challenge
Advanced therapy medicinal products (ATMPs) are a game changer for improving the life of patients with severe to life-threatening diseases. In hematology, for instance, CAR T cell therapy has shown promising results in tackling different blood cancers.
Read moreEU health policy: limited scope, high ambition
Over the past decades, the European Union (EU) has become more involved in public health policy. A recent study showed that a majority of policymakers even identifies EU health policy as a priority for 2020-20241.
Read moreRevising the ICH Guidelines on Clinical Trials
The EHA delegation to the ICH meeting: from left to right, Professors Christian Gisselbrecht, Steven Le Gouill and Martin Dreyling. Clinical trials and drug development have become more complex over the years.
Read moreFUNDING ALERT: Calls published on ATMPs, T cells and cancer research
In recent weeks, two Calls for proposals were published that offer relevant funding opportunities for hematologists:
1.
Rolling out CAR T across Europe
Prof Christine Chomienne talking about CAR T implementation challenges during the 7th EAPM Presidency Conference in Brussels.
Read moreTackling Sickle Cell Disease: the need for a European approach
Elvie Ingoli, president of the German association of SCD and thalassemia patients, at the 7th EAPM Presidency Conference in Brussels. Sickle Cell Disease (SCD) is relatively new to many parts of Europe.
Read moreHARMONY: Big data for better and faster treatment
HARMONY Alliance: A European Network of Excellence for Big Data in Hematology - Enabling Better and Faster Treatment based on Big Data technologies
Despite data being a key driver for modern evidence-based medicine, we have been struggling with the same challenge for…
Mission ‘Gene Therapy’ for Horizon Europe
Mission ‘Gene Therapy’ for Horizon Europe
Advanced therapies, such as gene therapy, hold promise for treating a wide range of chronic diseases and improving patients’ quality of life.
Uptake of CAR T cell therapy in Europe
Gene (editing) therapy continues to break ground in hematology, showing promising results in tackling severe blood cancers. Yet, its uptake in the European Union is slow, with few patients benefiting from it so far.
Read more